BREAST

 

Adjuvant
D-Care/Amgen 20060359 – PI:  Dr. Weibel
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 STUDY OF DENOSUMAB AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER AT HIGH RISK OF RECURRENCE. 

Locally Advanced or Metastatic
Her2 negativeGeron Corp CPI4B014 – PI: Dr. Weibel
A RANDOMIZED PHASE II STUDY OF IMETELSTAT (grn163l) IN COMBINATION WITH PACLITAXEL WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH LOCAL RECURRENT OR METASTATIC BREAST 

 

 

 

COLON

 

Observational Only:
Sanofi Aventis DIREG_C_04823 – Registration Trial – A prospective, non-interventional, co-hort survey on VTE risk in patients receiving new chemotherapy for cancer.   

Metastatic:
4130-CL-0201 Astellas pharma trial – A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination with mFOLFOX6 with Bevacizumab in Combination with mFOLFOX6 in Stage IV Metastatic Colorectal Cancer Subjects 

Lilly 14T-MC-JVBB/ IMCL CP12-0920– OPEN – PI:  Dr. Cole
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients with Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy with Bevacizumab, Oxaliplatin and Fluoropyrimidine 

Lilly Protocol I1Y-MC-JFBF  - PI:  Dr. Olsen
A Phase 2 Indication Identification Study of LY2523355 in Patients with Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck

 

 

 

GASTROESOPHAGEAL 

 

 Lilly Protocol I1Y-MC-JFBF  - PI:  Dr. Olsen
A Phase 2 Indication Identification Study of LY2523355 in Patients with Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck

 

 

 

HEAD & NECK

 

Lilly Protocol I1Y-MC-JFBF  - PI:  Dr. Olsen
A Phase 2 Indication Identification Study of LY2523355 in Patients with Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck

 

 

LEUKEMIA

Observational Only:
CA180-330  BMS–PI:  Dr. Strnad
STUDYING INTERVENTIONS FOR MANAGING PATIENTS WITH  CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE:  The 5 Year Prospective Cohort Study (SIMPLICITY)

 

 

LUNG

 

Observational Only:
VEEDA 11-005 – Sanofi Aventis DIREG_C_04823 – Registration Trial – A prospective, non-interventional, co-hort survey on VTE risk in patients receiving new chemotherapy for cancer.  

Non-Small Cell
Lilly H3E-US-S130 – PI:  Dr. Olsen
RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF PEMETREXED PLUS CARBOPLATING FOLLOWED BY MAINTENANCE PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER OF NONSQUAMOUS HISTOLOGY 

Lilly I4T-MC-JVBA(b)/ IMCL CP12-1027 – PI:  Dr. Buck
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF DOCETAXEL AND RAMUCIRUMAB VERSUS DOCETAXEL AND PLACEBO IN THE TRATMENT OF STAGE IV NSCLC FOLLOWING DISEASE PROGRESSION AFTER ONE PRIOR PLATINUMB-BASED THERAPY 

Lilly Protocol I1Y-MC-JFBF - PI:  Dr. Olsen
A Phase 2 Indication Identification Study of LY2523355 in Patients with Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck 

Non-Small Cell: Squamous
BMS CA184104 – PI:  Dr. BuckRANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 TRIAL COMPARING THE EFFICACY OF IPILIMUMAB IN ADDITION TO PACLITAXEL AND CARBOPLATIN VERSUS PLACEBO IN ADDITION TO PACLITAXEL AND CARBOPLATIN IN SUBJECTS WITH STAGE IV/RECURRENT NON-SMALL CELL LUNC CANCER (NSCLC) 

Small-Cell
BMS CA184156 – PI:  Dr. Buck
RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 TRIAL COMPARING THE EFFICACY OF IPILIMUMAB PLUS ETOPOSIDE/PLATINUM VERSUS ETOPOSIDE/PLATINUM IN SUBJECTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE DISEASE SMALL CELL LUNG CANCER  

 

 

  

 LYMPHOMA

 

C05013 Millennium Pharmaceuticals, Inc - PI:  Dr. Strnad
AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY TO ASSESS THE EFFECTIVENESS OF RCHOP WITH OR WITHOUT VELCADE IN PREVIOUSLY UNTREATED PATIENTS WITH NON-GERMINAL CENTER-B-CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA – PYRAMID Study

 

 

PANCREATIC

 

CA046 – Abraxis BioScience/Celgene Pharma Trial – PI:  Dr. Olsen
A RANDOMIZED PHASE III STUDY OF WEEKLY ABI-007 PLUS GEMCITABINE VERSUS GEMCITABINE ALONE IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS

 

 

                                                               

PROSTATE

CA184095  Bristol-Myers Squibb pharma trial – PI:  Dr. Olsen
RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL TO COMPARE THE EFFICACY OF IPILIMUMAB VS PLACEBO IN ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC PATIENTS WITH METASTATIC CHEMOTHERPY-NAÏVE CASTRATION RESISTANT PROSTATE CANCER   

Lilly Protocol I1Y-MC-JFBF  - PI:  Dr. Olsen
A Phase 2 Indication Identification Study of LY2523355 in Patients with Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck 

 

 

   SOFT TISSUE SARCOMA

 

IPM3001 Ziopharm pharma trial – PICASSO III – PI:  Dr. Olsen
A PHASE III MULTICENTER, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF DOXORUBICIN PLUS PALIFOSFAMIDE-TRIS VERSUS DOXORUBICIN PLUS PLACEBO IN PATEITNS WITH FRONT-LINE METASTATIC SOFT TISSUE SARCOMA